Retinitis Pigmentosa

Zhongmou Therapeutics Reports First-in-Human Success of Optogenetic Gene Therapy ZM-02 for Retinitis Pigmentosa

2 months ago talkbio0Tagged AAV Vector, First-in-Human Clinical Trial, gene therapy, Ophthalmology specialty, Optogenetic Gene Therapy, PsCatCh2.0, Retinitis Pigmentosa, Vision Restoration, Zhongmou, ZM-02

Zhongmou Therapeutics; Optogenetic Gene Therapy; ZM-02; Retinitis Pigmentosa; First-in-Human Clinical Trial; Vision Restoration; AAV Vector; PsCatCh2.0; Gene Therapy; Ophthalmology

AviadoBio Secures Option to Develop Rare Eye Disease Gene Therapy UGX-202 in $413 Million Deal with China’s UgeneX

3 months ago talkbio0Tagged AviadoBio, China, gene therapy, Optogenetics, Retinitis Pigmentosa, UgeneX, UGX-202

AviadoBio; UgeneX; UGX-202; optogenetics; gene therapy; retinitis pigmentosa; China; $413 million deal

AviadoBio Secures Option to UgeneX’s UGX-202 Gene Therapy for Retinal Disease

3 months ago talkbio0Tagged AviadoBio, Clinical Development, Dependovirus, gene therapy, Optogenetics, Retinal Diseases, Retinitis Pigmentosa, UGX-202

AviadoBio; UgeneX Therapeutics; UGX-202; retinitis pigmentosa; gene therapy; optogenetics; adeno-associated virus (AAV); exclusive option; retinal disease; clinical development